J CLIN INVEST :为什么有的人服用高血压药副作用严重 基因决定血压药物副作用

2017-08-08 佚名 来宝网

近日,来自诺丁汉大学的科学家们发现,有些病人的基因决定了他们对常见血压药会出现严重的副作用。

近日,来自诺丁汉大学的科学家们发现,有些病人的基因决定了他们对常见血压药会出现严重的副作用。

15年的努力成果显示,少数病人在服用高血压药物时,他们的基因会由于噻嗪类利尿剂的影响发展成低钠血症。他们的研究结果发表在《临床研究杂志》上,在报告中,研究人员指出,血液和尿液测试表明,药物会在体内微妙的持续很久之后才会消除。

在近50年来,噻嗪类利尿剂是最广泛用于高血压的有效药物,除此之外,它还可以防止高血压患者出现心脏病发作和中风。尽管绝大多数患者都没有出现严重的副作用,但是少数人会由于噻嗪类诱导出低血钠症TIH,这在医学上非常严重。

目前唯一的方法检测TIH的方法使在开始服药几周后接受血液测试监控,然而,不幸的是,低血钠症有时发生在测试之前,有时又发生在测试之后,因此,不容易被发现。在此次研究中,科学家利用遗传分析和生化特性描述来自157名确诊为由噻嗪类导致的低血钠症患者的血液和尿液样本,用以发现他们与其他人的不同之处。为了进一步确认研究结果,研究人员也分析了246例服用噻嗪类药物,但血液中的钠含量正常的高血压患者资料。

研究人员表示:“此次研究结果告诉我们,在未来我们需要个性化治疗高血压患者,确定噻嗪类的副作用人群,找到其他的替代药品。”

原始出处:
James S. Ware, Louise V. Wain, Sarath K. Channavajjhala,et al.Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia.J CLIN INVEST.August 7, 2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824250, encodeId=a1c6182425046, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Tue May 01 19:08:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050809, encodeId=7a912050809e6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 16 10:08:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231521, encodeId=87b823152123, content=完全没听过,新东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIkNwCMvcaJiclcUnbibMY8aNMrNCO1ZwiaS6Na5waERicZaIP2UbGVwHvdnTVHwOetJuQoy1zFYyCGqw/0, createdBy=d8891630715, createdName=成恩, createdTime=Tue Aug 08 15:28:39 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231515, encodeId=ec9b231515b1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Aug 08 14:48:50 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231488, encodeId=a6fd2314887e, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Aug 08 14:39:01 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231485, encodeId=0135231485b4, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Aug 08 14:33:35 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824250, encodeId=a1c6182425046, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Tue May 01 19:08:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050809, encodeId=7a912050809e6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 16 10:08:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231521, encodeId=87b823152123, content=完全没听过,新东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIkNwCMvcaJiclcUnbibMY8aNMrNCO1ZwiaS6Na5waERicZaIP2UbGVwHvdnTVHwOetJuQoy1zFYyCGqw/0, createdBy=d8891630715, createdName=成恩, createdTime=Tue Aug 08 15:28:39 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231515, encodeId=ec9b231515b1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Aug 08 14:48:50 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231488, encodeId=a6fd2314887e, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Aug 08 14:39:01 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231485, encodeId=0135231485b4, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Aug 08 14:33:35 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824250, encodeId=a1c6182425046, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Tue May 01 19:08:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050809, encodeId=7a912050809e6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 16 10:08:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231521, encodeId=87b823152123, content=完全没听过,新东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIkNwCMvcaJiclcUnbibMY8aNMrNCO1ZwiaS6Na5waERicZaIP2UbGVwHvdnTVHwOetJuQoy1zFYyCGqw/0, createdBy=d8891630715, createdName=成恩, createdTime=Tue Aug 08 15:28:39 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231515, encodeId=ec9b231515b1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Aug 08 14:48:50 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231488, encodeId=a6fd2314887e, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Aug 08 14:39:01 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231485, encodeId=0135231485b4, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Aug 08 14:33:35 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 成恩

    完全没听过,新东西

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1824250, encodeId=a1c6182425046, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Tue May 01 19:08:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050809, encodeId=7a912050809e6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 16 10:08:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231521, encodeId=87b823152123, content=完全没听过,新东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIkNwCMvcaJiclcUnbibMY8aNMrNCO1ZwiaS6Na5waERicZaIP2UbGVwHvdnTVHwOetJuQoy1zFYyCGqw/0, createdBy=d8891630715, createdName=成恩, createdTime=Tue Aug 08 15:28:39 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231515, encodeId=ec9b231515b1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Aug 08 14:48:50 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231488, encodeId=a6fd2314887e, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Aug 08 14:39:01 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231485, encodeId=0135231485b4, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Aug 08 14:33:35 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 Y—xianghai

    学习了新知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1824250, encodeId=a1c6182425046, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Tue May 01 19:08:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050809, encodeId=7a912050809e6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 16 10:08:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231521, encodeId=87b823152123, content=完全没听过,新东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIkNwCMvcaJiclcUnbibMY8aNMrNCO1ZwiaS6Na5waERicZaIP2UbGVwHvdnTVHwOetJuQoy1zFYyCGqw/0, createdBy=d8891630715, createdName=成恩, createdTime=Tue Aug 08 15:28:39 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231515, encodeId=ec9b231515b1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Aug 08 14:48:50 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231488, encodeId=a6fd2314887e, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Aug 08 14:39:01 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231485, encodeId=0135231485b4, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Aug 08 14:33:35 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 1e0e5697m83(暂无匿称)

    henhao

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1824250, encodeId=a1c6182425046, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Tue May 01 19:08:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050809, encodeId=7a912050809e6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jun 16 10:08:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231521, encodeId=87b823152123, content=完全没听过,新东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIkNwCMvcaJiclcUnbibMY8aNMrNCO1ZwiaS6Na5waERicZaIP2UbGVwHvdnTVHwOetJuQoy1zFYyCGqw/0, createdBy=d8891630715, createdName=成恩, createdTime=Tue Aug 08 15:28:39 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231515, encodeId=ec9b231515b1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Aug 08 14:48:50 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231488, encodeId=a6fd2314887e, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Tue Aug 08 14:39:01 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231485, encodeId=0135231485b4, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Aug 08 14:33:35 CST 2017, time=2017-08-08, status=1, ipAttribution=)]
    2017-08-08 王秀

    学习了,涨知识了!

    0

相关资讯

4大疾病领域基因疗法管线大盘点

自转基因技术于上世纪70年代问世以来,基因疗法就被视为解决许多疾病,尤其是遗传病的终极疗法。过去二三十年来基因工程领域取得了突飞猛进的发展,但是,将基因疗法应用到人身上的过程却并非一帆风顺。基因疗法的长期有效性和长期安全性是这一领域的主要瓶颈。 2017年对于基因疗法来说可能是里程碑的一年,美国FDA有望批准Spark公司voretigene neparvovec用于治疗由RPE65突变引起

EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗

约25%~30%的非小细胞肺癌为鳞癌。肺鳞癌的治疗可选性相对较小。在晚期肺鳞癌治疗中,培美曲塞单药和联合治疗未被批准,血管内皮生长因子受体抑制剂贝伐珠单抗(bevacizumab)因易伴随出血事件而被禁用。针对驱动基因变异的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)和间变性淋巴瘤激酶酪氨酸激酶抑制剂(ALK-TKI)在晚期肺鳞癌中的靶向治疗已有一些研究报道。本文对EGFR-TKI在EGF

Nat Commun:新研究发现缩短寿命的16个遗传标记

近日,研究人员已经确定了与寿命缩短相关的16个遗传标记,其中包括14个新遗传标记。这是迄今为止发现的最大的一组寿命标记。约有10%的人口携带部分标记,与平均人口相比,他们的寿命缩短了一年以上。

JCEM:关于自身免疫多腺体综合征又有了新发现!

自身免疫多腺体综合征1型(APS-1)是一种罕见的单基因遗传的自身免疫性疾病,是由自身免疫调节因子(AIRE)基因突变引起的,表现为慢性皮肤粘膜念珠菌病(CMC)、甲状旁腺功能减退症(HP)和原发性肾上腺皮质功能不全(AI)。然而大队列患者的综合表征却缺乏。

张锋教授Nature发文,CRISPR技术找到了癌症免疫疗法关键基因!

要说近年来癌症领域取得的最大突破,那莫过于免疫疗法了。一些原本等同于死刑判决的恶性癌症,在免疫疗法的作用下,竟能连续10多年不复发,这近乎达到了治愈的效果,堪称奇迹。 但免疫疗法也不是万能的。肿瘤细胞一直在快速突变,而有些突变会让免疫疗法失效。目前我们知道,B2M、JAK1与JAK2基因一旦发生突变失活,就会让免疫疗法失去应有的作用。

Cell:图谱!1篇论文揭秘769个癌症“关键”基因

7月27日,发表在Cell杂志上题为“Defining a Cancer Dependency Map”的研究成果中,来自Broad研究所和Dana-Farber癌症研究所的科学家们建立了癌细胞遗传弱点的综合目录。具体来说,研究人员鉴定出了超过760个癌细胞生长和生存强烈依赖的基因。其中,许多依赖性(dependencies)是针对某些特定的癌症类型,另外,有约10%的依赖性在多种癌症中是共同存在